17 November 2004, Sydney: Imugene (ASX IMU) today announced that
analysis of the initial batch of the test vaccine used in the recent Avian Influenza
pilot trial (reported in October 2004) revealed a batch defect which is now being
corrected. Whilst uncommon, technical defects in early batches can occur with
this technology and can be resolved.
“The pilot trial results were unexpected. We now know that it was the batch
rather than the actual vaccine that was the problem with the pilot trial,” stated Dr
Warwick Lamb, Managing Director of Imugene. “The gene used is the correct
protective gene and once we get correct expression of this gene, we expect
effective protection against the Avian Influenza.”
global commercial potential , page-2
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.6¢ |
Change
-0.003(4.31%) |
Mkt cap ! $409.9M | |||
| Open | High | Low | Value | Volume |
| 5.7¢ | 5.8¢ | 5.5¢ | $304.7K | 5.413M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 29 | 2910244 | 5.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.6¢ | 531755 | 14 |
View Market Depth
| Last trade - 11.33am 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
5.7¢ |
Change
-0.003 ( 1.05 %) |
||||
| Open | High | Low | Volume | ||
| 5.7¢ | 5.7¢ | 5.5¢ | 2041448 | ||
| Last updated 11.54am 17/06/2024 ? | |||||
| IMU (ASX) Chart |
